GLP-1 Receptor Agonist is a research-grade single-pathway incretin peptide supplied in lyophilized vial format for controlled laboratory work examining single-pathway incretin receptor signaling and comparative peptide-pathway models
Repeated injections in identical locations create cumulative irritation and increase itching severity
[DOI] [PMC free article] [PubMed] [Google Scholar] 20.Svetkey LP, et al
Huss adds
Keep the vial tightly sealed
Immediate medical attention (emergency department or urgent care) is warranted for: Signs of anaphylaxis or severe allergic reaction, including difficulty breathing, throat tightness, rapid pulse, dizziness, or widespread urticaria (call 911) Severe swelling extending beyond the injection site or involving the face, lips, or tongue Signs of significant infection, including fever above 100.4F (38C), purulent drainage, or rapidly spreading erythema with warmth Severe pain disproportionate to visible findings Skin necrosis, blistering, or ulceration at the injection site Scheduled healthcare provider evaluation is appropriate for: Persistent injection site reactions lasting more than 5 to 7 days despite conservative management Recurrent moderate to severe reactions with each injection, suggesting possible hypersensitivity Development of indurated nodules or lipohypertrophy at injection sites Uncertainty about whether symptoms represent normal reactions or require intervention Clinical assessment of concerning injection site reactions typically includes examination of the affected area, review of injection technique, and evaluation for signs of infection or hypersensitivity
